联合治疗下炎症性肠病缓解期患者撤除免疫调节剂或TNF拮抗剂的系统评价与Meta分析
该系统评价纳入截至2023年3月31日的8项随机对照试验共733例患者(77%为克罗恩病,91%为英夫利西单抗联合治疗),评估联合治疗下持续无激素临床缓解超过6个月的炎症性肠病患者撤除免疫调节剂或TNF拮抗剂的有效性与安全性,主要结局为12个月复发风险和严重不良事件。Meta分析显示,撤除免疫调节剂(继续TNF拮抗剂单药)与继续联合治疗相比复发风险无差异,撤除TNF拮抗剂(继续免疫调节剂单药)与继续联合治疗相比复发风险升高约2.4倍,两者严重不良事件风险均无差异。
要点
- 撤除免疫调节剂(继续TNF拮抗剂单药)与继续联合治疗相比,12个月复发风险无差异(RR 1.15,95%CI 0.75-1.76)。
- 撤除TNF拮抗剂(继续免疫调节剂单药)与继续联合治疗相比,复发风险升高(RR 2.35,95%CI 1.38-4.01)。
- 撤除免疫调节剂或TNF拮抗剂与继续联合治疗相比,严重不良事件风险均无差异。
核心结论
- 在联合治疗下持续无激素临床缓解超过6个月的炎症性肠病患者中,撤除TNF拮抗剂(而非撤除免疫调节剂)与复发风险增加相关。
研究设计与样本
- 系统评价与Meta分析,检索截至2023年3月31日,纳入8项随机对照试验共733例患者(77%为克罗恩病,91%为英夫利西单抗联合治疗)。
- 纳入标准为联合治疗下持续无激素临床缓解超过6个月的炎症性肠病患者,比较撤除免疫调节剂或TNF拮抗剂与继续联合治疗的疗效与安全性。
主要发现
- 5项随机对照试验的Meta分析显示,撤除免疫调节剂(继续TNF拮抗剂单药)与继续联合治疗相比,12个月复发风险无差异(16.8% vs 14.9%;RR 1.15;95%CI 0.75-1.76),无异质性(低确定性证据)。
- 撤除TNF拮抗剂(继续免疫调节剂单药)与继续联合治疗相比,12个月复发风险升高(31.5% vs 11.2%;RR 2.35;95%CI 1.38-4.01),异质性极小(低确定性证据)。
- 撤除免疫调节剂或TNF拮抗剂与继续联合治疗相比,严重不良事件风险均无差异。
关键数值与推荐
- 撤除免疫调节剂(继续TNF拮抗剂单药)vs 继续联合治疗:12个月复发率16.8% vs 14.9%,RR 1.15(95%CI 0.75-1.76),低确定性证据。
- 撤除TNF拮抗剂(继续免疫调节剂单药)vs 继续联合治疗:12个月复发率31.5% vs 11.2%,RR 2.35(95%CI 1.38-4.01),低确定性证据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 证据确定性为低(low certainty of evidence)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Withdrawal of immunomodulators (IMMs) or tumor necrosis factor (TNF) antagonists in patients with inflammatory bowel diseases (IBDs) in remission on combination therapy is attractive. We evaluated the efficacy and safety of (1) IMM, or (2) TNF antagonist withdrawal in patients with IBD in sustained remission on combination therapy. METHODS: Through a systematic review till March 31, 2023, we identified randomized controlled trials (RCTs) that compared the efficacy and safety of IMM or TNF antagonist withdrawal vs continued combination therapy, in patients with IBD in sustained corticosteroid-free clinical remission for >6 months on combination therapy. Primary outcome was risk of relapse and serious adverse events at 12 months. We conducted meta-analysis to calculate relative risk (RR) and 95% confidence interval (CI) and used Grading of Recommendations Assessment, Development and Evaluation (GRADE) to appraise certainty of evidence. RESULTS: We identified 8 RCTs with 733 patients (77% with Crohn's disease, 91% on infliximab-based combination therapy). On meta-analysis of 5 RCTs, there was no difference in the risk of relapse between patients with IMM withdrawal (continued TNF antagonist monotherapy) vs continued combination therapy (16.8% vs 14.9%; RR, 1.15; 95% CI, 0.75-1.76) without heterogeneity (low certainty of evidence). TNF antagonist withdrawal (continued IMM monotherapy) was associated with 2.4-times higher risk of relapse compared with continuing combination therapy (31.5% vs 11.2%; RR, 2.35; 95% CI, 1.38-4.01), with minimal heterogeneity (low certainty of evidence). There was no difference in the risk of serious adverse events with IMM or TNF antagonist withdrawal vs continued combination therapy. CONCLUSIONS: In patients with IBD in sustained corticosteroid-free clinical remission for >6 months on combination therapy, de-escalation with TNF antagonist withdrawal, but not IMM withdrawal, was associated with an increased risk of relapse.
引用
- Katibian DJ, Solitano V, Polk DB, et al. Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023. PMID: 37716619. doi:10.1016/j.cgh.2023.08.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。